Ivabradine Tablet, Film Coated
Product Images NDC 51407-592

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Ivabradine (NDC 51407-592). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-592-60ol .jpg (51407 592 60ol)

Label for Ivabradine 5 mg film-coated oral tablets by Golden State Medical Supply, Inc. The package contains 60 tablets and is for prescription use only. The label includes storage instructions, pharmacist dispensing advice, and a barcode. Strength and product details are clearly shown.*

FDA Label Image

51407-593-60ol.jpg (51407 593 60ol)

Ivabradine 7.5 mg film-coated tablets label by Golden State Medical Supply, Inc. The label indicates a package of 60 tablets for oral use, prescription only. It includes storage instructions, dosage reference, package safety info, and a barcode. The label also features the NDC 51407-593-60 and the GSMS logo.*

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 01)

Chemical structure of Ivabradine hydrochloride showing the molecular arrangement with methoxy, carbonyl, and nitrogen functional groups in the compound.*

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 02)

A forest plot chart illustrating the pharmacokinetic measures of ivabradine showing fold changes with 90% confidence intervals for different drug interactions. The chart compares changes in AUC and Cmax relative to ivabradine alone for CYP3A4 inhibitors, CYP3A4 inducers, and other drugs, with corresponding recommendations on use or dose adjustments.*

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 03)

A line graph comparing the proportion of patients experiencing heart failure hospitalization or cardiovascular death over 36 months between a placebo group and a Corlanor (ivabradine) group. The x-axis represents time from randomization in months, and the y-axis shows the proportion with these outcomes as a percentage. Below the graph, the number of subjects at risk in each group is listed at various time points.*

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 04)

A forest plot chart showing hazard ratios (HR) with 95% confidence intervals (CI) comparing Ivabradine tablets versus placebo across various population subgroups including age, sex, race, cause of heart failure, weight, baseline heart rate, NYHA class, baseline LV ejection fraction, beta blocker and aldosterone antagonist use, diabetes, and hypertension status. The chart illustrates the percentage of the total population in each subgroup with corresponding HR values, visually representing the comparative effect of Ivabradine tablets relative to placebo.*

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 05)

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 92 2)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.